Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCHE | P06276 | 3/20 | 0.58 |
| ▸ | MEN1 | O00255 | 3/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.58 |
| ▸ | NPC1 | O15118 | 1/20 | 0.55 |
| ▸ | POLB | P06746 | 1/20 | 0.55 |
| ▸ | RAB9A | P51151 | 1/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.55 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
| ▸ | HTT | P42858 | 1/20 | 0.52 |
| ▸ | MAOB | P27338 | 2/20 | 0.51 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.51 |
| ▸ | ATM | Q13315 | 1/20 | 0.50 |
| ▸ | PLA2G4B | P0C869 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5082780 | 0.96 | BCHE (0.54) | BCHEMEN1KMT2ANPC1POLB | |
| SCHEMBL5082286 | 0.94 | MAOB (0.56) | BCHENPC1RAB9ASMN1; SMN2FFAR1 | |
| SCHEMBL5076500 | 0.94 | MAOB (0.56) | BCHENPC1RAB9ASMN1; SMN2FFAR1 | |
| Hydrochloric Acid SCHEMBL5079981 | 0.93 | MAOB (0.55) | BCHENPC1RAB9ASMN1; SMN2FFAR1 | |
| Bromide SCHEMBL5078347 | 0.93 | MAOB (0.55) | BCHENPC1RAB9ASMN1; SMN2FFAR1 | |
| Oxalic Acid SCHEMBL5082796 | 0.92 | MAOB (0.53) | BCHEMEN1KMT2ANPC1RAB9A | |
| SCHEMBL5082682 | 0.90 | MAOB (0.51) | BCHENPC1POLBRAB9ASMN1; SMN2 | |
| SCHEMBL5082447 | 0.90 | MAOB (0.51) | BCHENPC1POLBRAB9ASMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL6212620 | 0.85 | SIGMAR1 (0.57) | BCHEMEN1KMT2ARAB9ASMN1; SMN2 | |
| SCHEMBL5082300 | 0.81 | NPC1 (0.53) | NPC1POLBRAB9ASMN1; SMN2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7408084-B2 | Process for producing optically active β-amino alcohol | KANEKA CORPORATION (JP) | 2008-08-05 | — | — | US | disclosed |
| US-20050277791-A1 | Process for producing optically active beta-amino alcohol | KANEKA CORPORATION (JP) | 2005-12-15 | — | — | US | disclosed |
| EP-1512677-A1 | PROCESS FOR PRODUCING OPTICALLY ACTIVE s-AMINO ALCOHOL | KANEKA CORPORATION (JP) | 2005-03-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050277791-A1 | Process for producing optically active beta-amino alcohol | ADH1A, ALDH7A1, ADH1C | BCHE 550/4885MEN1 3339/4885KMT2A 1460/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.